With dermatologists reporting issues with prior authorization requirements, Ortho Derm is offering several reduced-price products under a new cash-pay format.
Ortho Dermatologics Inc. has begun offering nine of its branded therapies at reduced, guaranteed prices through a network of pharmacies as a way to get around increasing prior authorization requirements that dermatologists report are causing delay, or denial, of prescribed treatments.
Unveiled during the recent American Association of Dermatology annual meeting, the program is meant to enable patients to bypass the...
As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.
Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Bourla said.
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
François Roger believes fixing inefficiencies is more important than playing with pricing.
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
